Michael Lowry (Tipperary North, Independent)
Link to this: Individually | In context | Oireachtas source

346. To ask the Minister for Health the steps he will take to ensure that Fampyra (details supplied) is made available to those with multiple sclerosis here; if he will review the decision made by the Health Service Executive not to fund Fampyra; and if he will make a statement on the matter. [36580/14]

Eric Byrne (Dublin South Central, Labour)
Link to this: Individually | In context | Oireachtas source

393. To ask the Minister for Health if and when he will include the drug Fampyra on the medical list which is used to help mobility for sufferers of multiple sclerosis; and if he will make a statement on the matter. [36840/14]

Gerry Adams (Louth, Sinn Fein)
Link to this: Individually | In context | Oireachtas source

422. To ask the Minister for Health if his attention has been drawn to the drug Fampyra and its benefits to sufferers of multiple sclerosis; if the Health Service Executive plans to license the drug here; if the HSE will provide for Fampyra on the medical card or serious illness card; and if he will make a statement on the matter. [36951/14]

Kathleen Lynch (Cork North Central, Labour)
Link to this: Individually | In context | Oireachtas source

I propose to take Questions Nos. 346, 393 and 422 together.

The Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement of medicinal products under the community drug schemes in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE received an application for the inclusion of Fampridine in the GMS and community drugs schemes. The application was considered in line with the procedures and timescales agreed by the Department of Health and the HSE with the Irish Pharmaceutical Healthcare Association for the assessment of new medicines. In accordance with these procedures, the National Centre for Pharmacoeconomics (NCPE) conducted a pharmacoeconomic evaluation of Fampridine and concluded that, as the manufacturer was unable to demonstrate the cost effectiveness of Fampridine in the Irish healthcare setting, it was unable to recommend the reimbursement of the product. The report is available on the NCPE's website ().

The HSE assessment process is intended to arrive at a decision on the funding of new medicines that is clinically appropriate, fair, consistent and sustainable. Due to the very difficult and challenging economic environment in which the Government targeted additional savings in health expenditure of €619 million in 2014, which must be achieved while protecting front line services to the most vulnerable to the greatest extent possible, the HSE decided it was not in a position to add the drug to the List of Reimbursable Items supplied under the GMS and other community drug schemes.

It is open to the supplier, at any time, to submit a new application to the HSE incorporating new evidence which demonstrates the cost effectiveness of Fampridine. Biogen Idec's Irish management indicated to the HSE in November 2013 that it intended to re-submit an application in April 2014. The HSE has advised it received a revised application from Biogen Idec on Friday 25th July. This application is currently being assessed in line with the agreed procedures and timescales. No further comment is possible at this time as the HSE decision making process is ongoing.